Journal of Clinical Oncology

Vol. 43, Issue 22 Issue 22 2025
14
Articles

Articles in this Issue

Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

Hervé Avet-Loiseau, Faith E. Davies, Mehmet K. Samur et al. Aug 01, 2025 pp. 2553-2553 10.1200/jco-25-01367

Reply to: Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Omission of Radiotherapy or Not?

Jianwei Zhang, Yue Cai, Lishuo Shi et al. Aug 01, 2025 pp. 2550-2552 10.1200/jco-25-00420

Phase I Study of <sup>131</sup> I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

Thomas Cash, Araz Marachelian, Steven G. DuBois et al. Aug 01, 2025 pp. 2490-2501 10.1200/jco-24-02612

PURPOSE We conducted a phase I trial to determine the safety, tolerability, and preliminary antitumor activity of 131 I-metaiodobenzylguanidine (...

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

Sikander Ailawadhi, Ivan Špička, Andrew Spencer et al. Aug 01, 2025 pp. 2527-2537 10.1200/jco-25-00744

PURPOSE To report the results of the multicenter, open-label IRAKLIA trial (ClinicalTrials.gov identifier: NCT05405166...

Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score–Matched Controlled Prospective Study

Adele De Masson, Marie Beylot-Barry, Caroline Ram-Wolff et al. Aug 01, 2025 pp. 2461-2466 10.1200/jco-25-00183

Cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and sometimes fatal diseases. Patients presenting with advanced-stage CTCL usually exhibit poor long-term survival outcomes. Only very...

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

Manuel González Fernández, Felipe Reyes-Cosmelli, Yovany Rodriguez Peña et al. Aug 01, 2025 pp. 2502-2514 10.1200/jco-25-00748

PURPOSE The phase III randomized open-label LEAP-015 study (ClinicalTrials.gov identifier: NCT04662710 ) evaluate...

Long-Term Dynamic Financial Impacts Among Adolescents and Young Adults With Cancer: A Longitudinal Matched-Cohort Study

Giancarlo Di Giuseppe, Arif Jetha, Petros Pechlivanoglou et al. Aug 01, 2025 pp. 2467-2478 10.1200/jco-24-02121

PURPOSE Surviving cancer has significant financial implications for adolescents and young adults (AYAs). It is unclear how cancer affects AYA income over time compared with the gen...

Erratum: Fertility Preservation in People With Cancer: ASCO Guideline Update

H. Irene Su, Christina Lacchetti, Joseph Letourneau et al. Aug 01, 2025 pp. 2553-2553 10.1200/jco-25-01373

Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Omission of Radiotherapy or Not?

Fengpeng Wu, Linlin Xiao, Guiying Wang Aug 01, 2025 pp. 2550-2550 10.1200/jco-25-00150

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

Jeff P. Sharman, Talha Munir, Sebastian Grosicki et al. Aug 01, 2025 pp. 2538-2549 10.1200/jco-25-00166

PURPOSE Pirtobrutinib, a noncovalent, Bruton tyrosine kinase inhibitor (BTKi), has shown clinical efficacy and a favorable safety profile. BRUIN CLL-321 was an open-label, randomiz...

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Mark N. Stein, Armelle Vinceneux, Debbie Robbrecht et al. Aug 01, 2025 pp. 2515-2526 10.1200/jco-25-00678

PURPOSE We report phase I trial results for pasritamig, a first-in-class, T-cell–engaging bispecific antibody targeting human kallikrein 2 (KLK2) expressed on the surface of prostate cance...

Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma

Paul H. McClelland, Shirley K. Nah, Alexandra M. Gustafson et al. Aug 01, 2025 pp. 2479-2489 10.1200/jco-24-02348

PURPOSE Acral lentiginous melanoma is a subtype of cutaneous melanoma arising from palmar, plantar, or subungual skin. These tumors are characterized by aggressive biology, a low tumor mut...

Enduring Economic Effects of a Cancer Diagnosis in Adolescence and Young Adulthood

Danielle Novetsky Friedman, Bridgette Thom Aug 01, 2025 pp. 2453-2455 10.1200/jco-25-01005

Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 Inhibitor

Ian F. Tannock, Qamar J. Khan, Tito Fojo Aug 01, 2025 pp. 2456-2460 10.1200/jco-24-02683

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page